Clinical Trial Update: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab [Phase 3]

View source ↗

Summary

Phase 3 trial assessing guselkumab in moderate-to-severe plaque psoriasis patients with inadequate response to ustekinumab; study completed with posted results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2017-07-17